National Brain Tumor Society Applauds Medicare’s Coverage Decision for Tumor Treatment Field Therapy
On the heels of the first-ever Glioblastoma Awareness Day (#GBMDay) in
As you know, there are only four drugs and one device currently approved by the
Medicare's decision is a patient advocacy win! This coverage determination will help patients access potentially life-extending treatment while reducing affordability as a barrier to glioblastoma care.
A special thank you to
The coverage determination and a summary response to comments are available in the CMS coverage database.
Association of British Insurers: Discount Rate Impact Assessment ‘Misleading and Wholly Disingenuous’
Hurricane Barry Estimated To Have Caused Between $500-$900M Of Losses
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News